Video: Study Reports Lower IOP, Fewer Medications With Omni

Researchers from Emory University reported meaningful IOP control and reduced glaucoma medications when combined with cataract surgery.

By: Rebecca F. Neustein, MD, Chelsea-Jane Arcalas, MD

Glaucoma Physician February 21, 2026

Clinical Report: Study Reports Lower IOP, Fewer Medications With Omni

Overview

A recent study presented at the American Glaucoma Society meeting demonstrated that the Omni surgical system, when combined with cataract surgery, achieved a higher rate of surgical success and a greater reduction in glaucoma medications compared to the Kahook dual blade (KDB) goniotomy. Specifically, the Omni group showed an 83.1% surgical success rate at 18 months, alongside a statistically significant reduction in medication use.

Background

The management of glaucoma often requires effective intraocular pressure (IOP) control to prevent vision loss. Minimally invasive glaucoma surgeries (MIGS) like the Omni system are increasingly being integrated into treatment pathways, particularly for patients undergoing cataract surgery. Understanding the efficacy and safety of these interventions is crucial for optimizing patient outcomes in glaucoma management.

Data Highlights

Reformat the table for clarity and ensure it aligns with clinical reporting standards.

Key Findings

The Omni group achieved a surgical success rate of 83.1% compared to 62.5% in the KDB group (P=0.03).
Reduction in glaucoma medications was greater in the Omni group (1.3 medications) than in the KDB group (0.6 medications).
Both groups experienced similar rates of postoperative complications (16% for Omni, 18% for KDB).
Statistically significant reduction in IOP was observed in both groups, although the confidence interval was wide.
The study had limitations, including a short follow-up period and unequal sample sizes.

Clinical Implications

The findings suggest that the Omni surgical system may offer superior outcomes in terms of surgical success and medication reduction for patients with glaucoma undergoing cataract surgery. Clinicians should consider the Omni system as a viable option in the treatment of glaucoma, particularly for patients with mild to moderate open-angle disease.

Conclusion

The study highlights the potential benefits of the Omni surgical system in achieving better surgical outcomes and reducing medication burden in glaucoma patients. Further research with larger sample sizes and longer follow-up is warranted to confirm these findings.

PentaVision

Glaucoma Physician